A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-center Trial to Evaluate the Efficacy and Safety of ONO-1110 in Patients With Fibromyalgia
Latest Information Update: 10 Jun 2025
At a glance
- Drugs ONO 1110 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ono Pharmaceutical
Most Recent Events
- 21 Feb 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Jan 2025 to 1 Mar 2025.
- 21 Feb 2025 Status changed from not yet recruiting to recruiting.
- 07 Jan 2025 New trial record